Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes.
Anna Meta Dyrvig KristensenManan PareekKristian Hay KragholmChristian Torp-PedersenJohn William McEvoyEva Irene Bossano PrescottPublished in: European journal of preventive cardiology (2023)
Aspirin therapy for primary prevention of CVD has decreased over the last two decades. However, the drug remained used in individuals with and without diabetes and a large proportion of individuals started on aspirin therapy had no CVD risk factors.
Keyphrases
- low dose
- cardiovascular disease
- type diabetes
- cardiovascular events
- risk factors
- high dose
- glycemic control
- antiplatelet therapy
- cardiovascular risk factors
- stem cells
- coronary artery disease
- drug induced
- skeletal muscle
- insulin resistance
- metabolic syndrome
- bone marrow
- adverse drug
- percutaneous coronary intervention